2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. 17β-HSD

17β-HSD

17beta-HSD; 17β-hydroxysteroid dehydrogenases; 17 beta-hydroxysteroid dehydrogenase

 

17β-HSD Isoform Specific Products:

17β-HSD Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148814
    BI-3231
    		Inhibitor 99.83%
    BI 3231 is a potent and selective hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases.
    BI-3231
  • HY-19903
    ASP-9521
    		Inhibitor ≥98.0%
    ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3.
    ASP-9521
  • HY-138557
    AKR1C3-IN-4
    		Inhibitor 99.77%
    AKR1C3-IN-4 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 0.56 μM. AKR1C3-IN-4 has the potential for castrate resistant prostate cancer (CRPC) research.
    AKR1C3-IN-4
  • HY-107379
    AKR1C3-IN-1
    		Inhibitor 98.23%
    AKR1C3-IN-1 is a potent, highly selective inhibitor of AKR1C3, with an IC50 of 13 nM.
    AKR1C3-IN-1
  • HY-155035
    S07-1066
    		Inhibitor 99.48%
    S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells.
    S07-1066
  • HY-161979
    HSD17B13-IN-103
    		Inhibitor
    HSD17B13-IN-103 (Compound 44) is a HSD17B13 inhibitor. HSD17B13-IN-103 can be used in the study of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
    HSD17B13-IN-103
  • HY-159651
    PTOTAC HSD17B13 degrader 1
    PTOTAC HSD17B13 degrader 1 (compound 1) is a PROTAC targeting 17β-HSD 13 (HSD17B13). PTOTAC HSD17B13 degrader 1 is composed of PROTAC target protein ligand HSD17B13 degrader 2 (HY-159662) (red part), PROTAC Linker tert-Butyl 5-bromoisoindoline-2-carboxylate (HY-W003696) (black part) and E3 ubiquitin ligase ligand E3 ligase Ligand 31 (HY-159660) (blue part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is E3 Ligase Ligand-linker Conjugate 114 (HY-159661)[1].
    PTOTAC HSD17B13 degrader 1
  • HY-W267205
    3-Acetyl-7-Hydroxycoumarin
    		Inhibitor
    3-Acetyl-7-Hydroxycoumarin (Compound 2) is a high selective 17-beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor. 3-Acetyl-7-Hydroxycoumarin shows a significant improvement of the inhibitory potency, with 57% inhibition of 17β-HSD1 at 6 μM. 3-Acetyl-7-Hydroxycoumarin is promising for research of hormone-dependent diseases, such as breast cancer and endometriosis.
    3-Acetyl-7-Hydroxycoumarin
  • HY-145433
    17β-HSD1-IN-1
    		Inhibitor 99.34%
    17β-HSD1-IN-1 (Compound 1) is a highly selective 17β-HSD1 inhibitor with IC50s of 5.6 and 3155 nM for 17β-HSD1 and 17β-HSD2, respectively. 17β-HSD1-IN-1 can be used for the research of non-small cell lung cancer (NSCLC).
    17β-HSD1-IN-1
  • HY-156735
    HSD17B13-IN-2
    		Inhibitor 99.72%
    HSD17B13-IN-2 (compound 1) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-2 has cell experimental activity.
    HSD17B13-IN-2
  • HY-156736
    HSD17B13-IN-3
    		Inhibitor 99.78%
    HSD17B13-IN-3 (compound 2) is a potent hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13) inhibitor. HSD17B13-IN-3 does not have cell experimental activity.
    HSD17B13-IN-3
  • HY-103394
    TC HSD 21
    		Inhibitor 99.14%
    TC HSD 21 is a potent 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) inhibitor with an IC50 of 14 nM. TC HSD 21 shows excellent selectivity over 17β-HSD isoenzymes and nuclear receptors.
    TC HSD 21
  • HY-161227
    HSD17B13-IN-43
    		Inhibitor 99.68%
    HSD17B13-IN-43 (11) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of <0.1 μM for Estradiol. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-43
  • HY-157627
    HSD17B13-IN-9
    		Inhibitor 99.92%
    HSD17B13-IN-9 (252) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with an IC50 of 0.01 μM for 50 nM HSD17B13. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-9
  • HY-161212
    HSD17B13-IN-8
    		Inhibitor 99.97%
    HSD17B13-IN-8 (1) is a 17β-Hydroxysteroid dehydrogenases (HSD17B13) inhibitor, with IC50 values of <0.1 μM for Estradiol and <1 μM for LTB3. Used in NAFLD (Nonalcoholic fatty liver diseases) research.
    HSD17B13-IN-8
  • HY-128145
    HSD17B13-IN-41
    		Inhibitor
    HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH.
    HSD17B13-IN-41
  • HY-159525
    Linustedastatum
    		Inhibitor
    Linustedastatum (Linustedastat) is a hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) inhibitor.
    Linustedastatum
  • HY-163243
    HSD17B13-IN-29
    		Inhibitor
    HSD17B13-IN-29 (Compound 53) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-29 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-29
  • HY-163249
    HSD17B13-IN-49
    		Inhibitor
    HSD17B13-IN-49 (Compound 81) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-49 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-49
  • HY-161229
    HSD17B13-IN-69
    		Inhibitor
    HSD17B13-IN-69 (Compound 11) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. HSD17B13-IN-69 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH, as well as drug-induced liver injury (DILI).
    HSD17B13-IN-69
17β-HSD Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.